Risedronic acid is an aminobisphosphonate derivative of etidronic acid and CALCIUM CHANNEL BLOCKER that inhibits BONE RESORPTION and is used for the treatment of OSTEOPOROSIS. Risedronic acid is a Bisphosphonate.
Your body is constantly breaking down old bone and making new bone tissue. If you have osteoporosis, your body breaks down more bone than it forms so gradually bone loss occurs and your bones become thinner and fragile. This is especially common in women after menopause (change of life). Many people with osteoporosis have no symptoms and you may not even know that you have it. However, osteoporosis makes you more likely to have fractures (break bones), especially in your spine, hips and wrists.
Risedronate has an affinity for hydroxyapatite crystals in bone and acts as an antiresorptive agent. At the cellular level, Risedronat inhibits osteoclasts. The osteoclasts adhere normally to the bone surface but show evidence of reduced active resorption.
ORAL Paget’s disease of bone: Adult: 30 mg once daily for 2 mth, repeat if necessary after 2 mth Interval. Treatment & prophylaxis of postmenopausal or corticosteroidinduced corticosteroidinduced osteoporosis: Adult: 5 mg daily. To minimize GI effects, take w/ at least 200 ml of water in an upright position on an empty stomach, at least 30 mm before breakfast & any other oral medication. Remain upright after taking the tab for at least 30 mm. Do not take at bedtime or before rising. Alternatively, for postmenopausal osteoporosIs, 35 mg once wkly or 75 mg on 2 consecutive days of each mth or 150 mg once a mth may be given. Increase bone mass in men w/ osteoporosis: Adult: 35 mg once wkly.
Please tell your doctor if you are taking or have recently taken any other medicines, including medicines obtained without a prescription specially aspirin or other NSAIDs. Antacids, supplements, or medicines that contain aluminum, calcium, magnesium, or other minerals can interfere with how your body absorbs Risedon. If you use these other medicines, do not take them for at least 30 minutes after taking a Risedon tablet.
Acute upper GI inflammation, pregnancy, hypocalcaemia & CrCl <30 ml/ min. Correct hypocalcaemia prior to therapy. Monitor hepatic & renal function & WBC. Renal impairment; inability to remain in an upright position for at least 30 mm after oral intake.
Electrolyte disturbances; Gl disturbances; musculoskeletal pain; headache; hypersensitivity reactions; blood disorders; liver enzyme disturbances. Bone, joint and/or muscle pain.
Risedronate falls into category C. In animal studies, pregnant animals were given this medication and had some babies born with problems. No well-controlled studies have been done in humans. Therefore, this medication may be used if the potential benefits to the mother outweigh the potential risks to the unborn child. Tell your doctor before using risedronate if you are breastfeeding or plan to breastfeed. It is not known if risedronate is excreted in human breast milk or if it can harm your baby.
No specific information is available on the treatment of overdose with Risedon. Decreases in serum calcium following substantial overdose may be expected. Signs and symptoms of hypocalcaemia may also occur in some of these patients. Milk or antacids containing magnesium, calcium or aluminium should be given to bind Risedon and reduce absorption of Risedon. In cases of substantial overdose, gastric lavage may be considered to remove unabsorbed Risedon.
Store in a cool and dry place. Protect from light & moisture. Keep out of the reach of children.
.png&w=384&q=75)